These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38797892)

  • 1. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.
    Friedrich S; Chua L; Adams DH; Crandall W; Zhang XC
    Clin Pharmacol Ther; 2024 Aug; 116(2):435-447. PubMed ID: 38797892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.
    Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
    J Crohns Colitis; 2024 Nov; 18(11):1845-1856. PubMed ID: 38869019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
    Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
    Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis.
    Moćko P; Koperny M; Śladowska K; Holko P; Kowalska-Bobko I; Kawalec P
    Pharmacotherapy; 2024 Oct; 44(10):811-821. PubMed ID: 39320112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Nov; 58(11):1134-1139. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Gibble TH; Abreu MT; Lee SD; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Panaccione R; Dignass A
    Inflamm Bowel Dis; 2024 Oct; ():. PubMed ID: 39448057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirikizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
    Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
    Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
    J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
    Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
    Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.